A new oral prodrug of the Aβ aggregation modulator GAL-201 shows significantly improved pharmacokinetic profile
March 2026, AD/PDTM: Advances in Science &Therapy
Author: wamrhein
Stopping Neurodegeneration at its Source with GAL-101
December 2025, 18th Clinical Trials on Alzheimer’s Disease (CTAD)
Innovations in eDREAM, a Phase 2 Clinical Trial in Geographic Atrophy
September 2025, EURETINA Innovation Spotlight
Multimedia
Multimedia
Go back
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
-
Video Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nos commodius agimus. Quae est igitur causa istarum angustiarum? Gloriosa ostentatio in constituendo summo bono. Hic ambiguo ludimur. Iam contemni non poteris.
Drug Discovery News
An anti-amyloid drug for blindness
The Medicine Maker
A small molecule drug candidate for Alzheimer’s treatment
SCRIP Asks
What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
The amyloid beta aggregation modulator GAL-201 is under development for oral AD treatment: Cognitive improvement in a transgenic AD model
March 2024, AD/PD™ 2024: Advances in Science & Therapy
SCRIP
Scrip Asks…What Does 2024 Hold For Biopharma?
Part 2: The Funding Environment, M&A And Partnering
Going Public
Kleine Moleküle mit Großer Wirkung